Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Farlow, M. R.
Right arrow Articles by Charles, H. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Farlow, M. R.
Right arrow Articles by Charles, H. C.
Related Collections
Right arrow All Neuropsychology/Behavior
Right arrow All Cognitive Disorders/Dementia
Right arrow Alzheimer's disease
Right arrow MCI (mild cognitive impairment)
Right arrow Risk factors in epidemiology
NEUROLOGY 2004;63:1898-1901
© 2004 American Academy of Neurology

Impact of APOE in mild cognitive impairment

M. R. Farlow, MD, Y. He, PhD, S. Tekin, MD, J. Xu, PhD, R. Lane, MD and H. C. Charles, PhD

From the Department of Neurology (Dr. Farlow), Indiana University School of Medicine, Indianapolis, IN; Clinical Pharmacogenetics (Dr. He), Novartis Pharmaceuticals Corporation, Gaithersburg, MD; Novartis Pharmaceuticals Corporation (Drs. Tekin, Xu, and Lane), East Hanover, NJ; and Duke University Medical Center (Dr. Charles), Durham, NC.

Address correspondence and reprint requests to Dr. M. Farlow, Department of Neurology, Clinical Building, Room 299, 541 Clinical Drive, Indiana University School of Medicine, Indianapolis, IN 46202-5111; e-mail: mfarlow{at}iupui.edu

Objective: The authors aimed to use baseline data of an ongoing large, prospective study in subjects with mild cognitive impairment (MCI) to investigate the impact of APOE genotype on the symptom profile of the condition.

Methods: Cognitive assessments included the AD Assessment Scale cognitive subscale (ADAS-cog), the Mini-Mental State Examination (MMSE), and a cognitive battery for assessment of memory, attention, and executive function. Behavioral assessments included the Neuropsychiatric Inventory and Beck Depression Inventory. Activities of daily living were assessed by the AD Cooperative Study Activities of Daily Living (ADCS-ADL) scale. Hippocampal volumes were measured with MRI.

Results: A total of 494 of 1,018 study subjects provided APOE data. Approximately 40% of the subjects were APOE {epsilon}4 carriers. APOE {epsilon}4 carriers had lower MMSE (p = 0.01) and higher ADAS-cog (p < 0.0001) scores than noncarriers, indicating worse cognitive impairment. APOE {epsilon}4 carriers also had greater deficits on New York University delayed paragraph recall and Buschke free and cued selective reminding tests, and on the ADCS-ADL scale (p < 0.001). They also had smaller hippocampal volumes (p = 0.002). Behavioral scores were similar across the subgroups.

Conclusion: MCI subjects carrying the APOE {epsilon}4 allele showed distinct cognitive and imaging profiles, which appeared to resemble those of early Alzheimer patients. APOE {epsilon}4 genotype was associated with greater impairments in memory and functional activities as well as hippocampal atrophy.

Received September 23, 2003. Accepted in final form July 21, 2004.

Y.H., S.T., J.X., and R.L. are employees of Novartis Pharmaceuticals Corporation. M.R.F. has received grant support and has served as a consultant and received honoraria from Novartis Pharmaceuticals Corporation. H.C.C. has no financial interest to declare.




This article has been cited by other articles:


Home page
 JAMAHome page
J. M. Ellison
A 60-Year-Old Woman With Mild Memory Impairment: Review of Mild Cognitive Impairment
JAMA, October 1, 2008; 300(13): 1566 - 1574.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
B. Winblad, S. Gauthier, L. Scinto, H. Feldman, G. K. Wilcock, L. Truyen, A. J. Mayorga, D. Wang, H. R. Brashear, J. S. Nye, et al.
Safety and efficacy of galantamine in subjects with mild cognitive impairment
Neurology, May 27, 2008; 70(22): 2024 - 2035.
[Abstract] [Full Text] [PDF]

Home page
 Age AgeingHome page
A. Kulminski, S. V. Ukraintseva, K. G. Arbeev, K. G. Manton, J. Oshima, G. M. Martin, and A. I. Yashin
Association between APOE {varepsilon}2/{varepsilon}3/{varepsilon}4 polymorphism and disability severity in a national long-term care survey sample
Age Ageing, May 1, 2008; 37(3): 288 - 293.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
J. R. Petrella, V. S. Mattay, and P. M. Doraiswamy
Imaging Genetics of Brain Longevity and Mental Wellness: The Next Frontier?
Radiology, January 1, 2008; 246(1): 20 - 32.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
J. Kim, M. H. Park, E. Kim, C. Han, S. A. Jo, and I. Jo
Plasma Homocysteine Is Associated with the Risk of Mild Cognitive Impairment in an Elderly Korean Population
J. Nutr., September 1, 2007; 137(9): 2093 - 2097.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
V Jelic, M Kivipelto, and B Winblad
Clinical trials in mild cognitive impairment: lessons for the future
J. Neurol. Neurosurg. Psychiatry, April 1, 2006; 77(4): 429 - 438.
[Abstract] [Full Text] [PDF]

Home page
 AJGPHome page
H. H. Feldman and C. Jacova
Mild Cognitive Impairment
Am J Geriatr Psychiatry, August 1, 2005; 13(8): 645 - 655.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
R. M. Lane and M. R. Farlow
Lipid homeostasis and apolipoprotein E in the development and progression of Alzheimer's disease
J. Lipid Res., May 1, 2005; 46(5): 949 - 968.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by AAN Enterprises, Inc.